Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7849 - 7856 of 12086 results
FDA Concludes Two-Day Public Hearing on Human Cell and Tissue Product (HCT/P) Regulatory Paradigm
September 16, 2016| Blog| Viewpoint
Sixth Circuit Rules That Theft of PII from Insurance Company Results in Article III Standing
September 16, 2016| Blog| Viewpoint
Examining Goodlatte's EB-5 Bill, As Deadline Looms
September 16, 2016| News
FDA Convenes Two-Day Public Hearing on Human Cell and Tissue Product Regulatory Paradigm
September 15, 2016| Alert| Viewpoint
September Privacy and Security Updates
September 15, 2016| Blog| Viewpoint
Massachusetts Regulatory Overhaul: Hospitals, Clinics, Dialysis Units, and Medical Marijuana – Oh My!
September 15, 2016| Blog| Viewpoint
Federal Circuit: Go whole-hog on validity below if you want to contest an independent determination of invalidity on appeal
September 15, 2016| Blog| Viewpoint
MintzTech Connect Industry News - September 2016
September 15, 2016| Article| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|